

## Press Release

### Cellzome Announces Achievement of Second and Third Milestones in Inflammation Alliance with GlaxoSmithKline

**Cambridge, United Kingdom and Heidelberg, Germany, 27<sup>th</sup> March 2009** - Cellzome Inc. announced today that it has successfully achieved two further milestones for programs in its strategic alliance with GlaxoSmithKline. The achievement of these second and third milestones triggers an individual payment for each milestone from GlaxoSmithKline. The amounts of these payments are undisclosed.

In September 2008, Cellzome and GlaxoSmithKline announced the signing of a worldwide strategic alliance which uses Cellzome's drug discovery and development capabilities and its proprietary *Kinobeads*<sup>™</sup> technology to identify, develop and market novel, kinase-targeted therapeutics to treat inflammatory diseases. GSK has exclusive options to license drug candidates from Cellzome's kinase programs directed against seven targets. Cellzome will develop these programs to clinical proof of concept, unless GSK elects to exercise its option earlier. Cellzome is eligible to receive success-based milestones from GSK as product candidates are advanced. The first milestone in the alliance was announced in December 2008.

Tim Edwards, CEO of Cellzome, said: "The achievement of three milestones so soon after establishing the alliance with GSK underlines the excellent progress we are continuing to make in this collaboration."

- ends -

**For more information please contact:**

**Cellzome:**

Tim Edwards  
Chief Executive Officer  
Tel: +49 (0) 6221-137 57-100  
press@cellzome.com

**Media contact:**

Hogarth Partnership  
John Olsen  
Tel: +44 (0) 207 357 9477

**About Cellzome Inc.**

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Cellzome is investing in the discovery and development of novel, selective, small-molecule kinase inhibitors as oral therapeutics for diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma.

Its pipeline is driven by *Kinobeads*<sup>™</sup>, a proprietary technology for studying the interaction of compounds simultaneously with multiple kinases in their native state. In addition to its alliance with GSK, Cellzome has a collaboration with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit [www.cellzome.com](http://www.cellzome.com).